Literature DB >> 23812729

Tropomyosin-4 correlates with higher SBR grades and tubular differentiation in infiltrating ductal breast carcinomas: an immunohistochemical and proteomics-based study.

Maria Kabbage1, Mounir Trimeche, Hela Ben Nasr, Philippe Hammann, Lauriane Kuhn, Bechr Hamrita, Karim Chahed.   

Abstract

The aim of this study is to evaluate tropomyosin-4 (TM4) expression in infiltrating ductal breast carcinomas (IDCAs), as well as its prognostic significance. Using a 2-DE/MALDI-TOF mass spectrometry investigation coupled with an immunohistochemical approach, we have assessed the expression of TM4 in IDCAs, as well as in other types of breast tumors. Proteomic analyses revealed an increased expression of tropomyosin-4 in IDCA tumors. Using immunohistochemistry, overexpression of tropomyosin-4 was confirmed in 51 additional tumor specimens. Statistical analyses revealed, however, no significant correlations between tropomyosin-4 expression and clinicopathological parameters of the disease including tumor stage, patient age, estrogen and progesterone receptor status, and lymph node metastasis occurrence. A significant association was found, however, with a high Scarf-Bloom-Richardson (SBR) grade, a known marker of tumor severity. Additionally, the SBR component showing a correlation with TM4 expression was the tubular differentiation status. This study demonstrates the upregulation of tropomyosin-4 in IDCA tissues, which may highlight its involvement in breast cancer development. Our findings also support a link between tropomyosin-4 expression and aggressiveness of IDCA tumors.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23812729     DOI: 10.1007/s13277-013-0939-0

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  40 in total

1.  Tubulin detyrosination is a frequent occurrence in breast cancers of poor prognosis.

Authors:  A Mialhe; L Lafanechère; I Treilleux; N Peloux; C Dumontet; A Brémond; M H Panh; R Payan; J Wehland; R L Margolis; D Job
Journal:  Cancer Res       Date:  2001-07-01       Impact factor: 12.701

Review 2.  Tropomyosins as interpreters of the signalling environment to regulate the local cytoskeleton.

Authors:  G M O'Neill; J Stehn; P W Gunning
Journal:  Semin Cancer Biol       Date:  2007-09-04       Impact factor: 15.707

3.  Proteomic studies in breast cancer (Review).

Authors:  Xian-Ju Qin; Bruce X Ling
Journal:  Oncol Lett       Date:  2012-01-18       Impact factor: 2.967

4.  Differential expression of tropomyosin forms in the microfilaments isolated from normal and transformed rat cultured cells.

Authors:  F Matsumura; J J Lin; S Yamashiro-Matsumura; G P Thomas; W C Topp
Journal:  J Biol Chem       Date:  1983-11-25       Impact factor: 5.157

Review 5.  Tropomyosin isoforms in nonmuscle cells.

Authors:  J J Lin; K S Warren; D D Wamboldt; T Wang; J L Lin
Journal:  Int Rev Cytol       Date:  1997

6.  Gamma-actin: unusual mRNA 3'-untranslated sequence conservation and amino acid substitutions that may be cancer related.

Authors:  C C Chou; R C Davis; M L Fuller; J P Slovin; A Wong; J Wright; S Kania; R Shaked; R A Gatti; W A Salser
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

7.  MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1).

Authors:  Shuomin Zhu; Min-Liang Si; Hailong Wu; Yin-Yuan Mo
Journal:  J Biol Chem       Date:  2007-03-15       Impact factor: 5.157

8.  Human fibroblast tropomyosin isoforms: characterization of cDNA clones and analysis of tropomyosin isoform expression in human tissues and in normal and transformed cells.

Authors:  R E Novy; J L Lin; C S Lin; J J Lin
Journal:  Cell Motil Cytoskeleton       Date:  1993

9.  Tropomyosin 4 expression is enhanced in dedifferentiating smooth muscle cells in vitro and during atherogenesis.

Authors:  Marouan Abouhamed; Stefan Reichenberg; Horst Robenek; Gabriele Plenz
Journal:  Eur J Cell Biol       Date:  2003-09       Impact factor: 4.492

10.  Expression of tropomyosin isoforms in benign and malignant human breast lesions.

Authors:  B Franzén; S Linder; K Uryu; A A Alaiya; T Hirano; H Kato; G Auer
Journal:  Br J Cancer       Date:  1996-04       Impact factor: 7.640

View more
  7 in total

1.  Distinct actin-tropomyosin cofilament populations drive the functional diversification of cytoskeletal myosin motor complexes.

Authors:  Theresia Reindl; Sven Giese; Johannes N Greve; Patrick Y Reinke; Igor Chizhov; Sharissa L Latham; Daniel P Mulvihill; Manuel H Taft; Dietmar J Manstein
Journal:  iScience       Date:  2022-05-30

2.  Differential expression and diagnostic significance of P53, MutS homologs 2, tropomyosin-4 in alpha-fetoprotein-negative hepatocellular carcinoma.

Authors:  Xuyang Gong; Ailong Huang
Journal:  J Clin Lab Anal       Date:  2020-05-03       Impact factor: 2.352

3.  Upregulation of tropomyosin alpha-4 chain in patients' saliva with oral squamous cell carcinoma as demonstrated by Phage display.

Authors:  Paula Cristina Batista Faria; Ana Paula Carneiro; Renata Binato; Rafael Nascimento; Paula Souza Santos; Deborah Fagundes; Sindeval José da Silva; Adriano Mota Loyola; Eliana Abdelhay; Luiz Ricardo Goulart
Journal:  Sci Rep       Date:  2019-12-05       Impact factor: 4.379

4.  Bcl2l10 induces metabolic alterations in ovarian cancer cells by regulating the TCA cycle enzymes SDHD and IDH1.

Authors:  Su-Yeon Lee; Jinie Kwon; Kyung-Ah Lee
Journal:  Oncol Rep       Date:  2021-03-02       Impact factor: 3.906

5.  Load-dependent modulation of non-muscle myosin-2A function by tropomyosin 4.2.

Authors:  Nikolas Hundt; Walter Steffen; Salma Pathan-Chhatbar; Manuel H Taft; Dietmar J Manstein
Journal:  Sci Rep       Date:  2016-02-05       Impact factor: 4.379

6.  The functional proteomics analysis of VEGF-treated human epithelial ovarian cancer cells.

Authors:  Fan Zhang; Cui Li; Hailing Liu; Yuexiang Wang; Yile Chen; Xiaoying Wu
Journal:  Tumour Biol       Date:  2014-09-06

7.  Acupuncture Regulates Serum Differentially Expressed Proteins in Patients with Chronic Atrophic Gastritis: A Quantitative iTRAQ Proteomics Study.

Authors:  Feng Li; Bai Yang; Yanan Liu; Tianying Tang; Cun Wang; Mei Li; Siyi Lv; Qin Qi; Huirong Liu; Zheng Shi; Huangan Wu; Xiaomei Wang
Journal:  Evid Based Complement Alternat Med       Date:  2021-06-14       Impact factor: 2.629

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.